LONDON - A drug that shows signs of halting Alzheimer’s disease could be prescribed within six months after US authorities approved it for “priority review”.
Charities welcomed the decision to fast-track Aducanumab, which could be targeted at those with early signs of dementia.
Alzheimer’s disease, the most common form of dementia in the UK, affects about 500,000 people here.
